Home » Blog » Big Data in Oncology Spotlight

Big Data in Oncology Spotlight


IP Blog | Dave Melin | November 19, 2015

data stethoscopeThis week in health care trends, our big data in oncology spotlight includes the complexities of health data, factors behind the healthcare spending slowdown, how UPMC cut their readmissions with the use of big data, how the government is using data to market the ACA to new customers, and how the use of words like “revolutionary” and “miracle” to describe new drugs can be misleading.

Understanding Personal Health Data: Not All Bits Are the Same

This article examines the complexities inherent in the transfer of electronic health data and compares to complex data from the financial, government, and media industries.

Prescription Drugs and the Slowdown in Health Care Spending

In this article, HealthAffairs digs into the factors underlying the recent health care spending decline including prescription drugs and drug patent expirations.

How UPMC Used Big Data and Integrated Care to Reduce Readmissions

A recent report states that “University of Pittsburgh Medical Center (UPMC), the nation’s second-largest integrated payer-provider network, cut readmissions from 16.5 percent in 2008 to 13 percent in 2015 with its access to both payer and hospital big data.”

Marketing the Marketplaces

As the next ACA enrollment period progresses, this analysis notes that “now enrollment gets harder. The customers considered those with the biggest incentives to enroll have already done so.” So what will the government do? Market: “Using data to “know the market” and direct outreach is an important page from the private-sector playbook that government is learning from.”

Study Finds Media Inflates Potential of Cancer Drugs

A recent study published in JAMA Oncology has found that “use in the media of terms like “revolutionary,” “groundbreaking,” and “miracle,” can frequently inflate the preliminary results of trials evaluating these drugs.” The analysis found that these sorts of terms were often used without any particular clinical evidence to support such claims, and that often the speakers were journalists who perhaps lacked the scientific expertise to comment more precisely on the capabilities of the drugs.

The articles above are from our dedicated Big Data in Oncology e-magazine. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *